https://www.selleckchem.com/pr....oducts/ro-20-1724.ht
In this review, we summarize emerging evidence of changes in the TME and how it can affect prognosis and responses to therapy. We also examine pre-clinical and clinical research aiming at modulating TME to increase proportion of patients who benefit from immune checkpoint inhibitors. The composition of the TME in breast cancer is likely dynamic and may be altered. These changes may lead to more or less responses to immunotherapy. Patients with Hodgkin lymphoma (HL) can achieve excellent response and survival rates following frontline
Curtir
Comentario
Compartilhar
